15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 4 firms covering Lyell Immunopharma Inc, 4 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets range widely, $20.00 to $45.00 (about 2.3x), a sign of real disagreement on valuation. The average target of $35.75 sits 175% above the current $13.00. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-2.09 next quarter toward $-7.86 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 ratings
Moderate Buy
Strong Buy00%
Buy4100%
Hold00%
Sell00%
Strong Sell00%
Based on 4 analysts giving stock ratings to Lyell Immunopharma Inc.
As of Jul, 4 of 4 firms rate LYEL a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
LYEL EPS & revenue forecast
EPS · NEXT QUARTER
$-2.09
Range $-2.35 – $-1.90 · 7 analysts · -2% YoY
Next period, 7 analysts expect Lyell Immunopharma Inc to earn $-2.09 a share (range $-2.35 – $-1.90), versus $-2.13 a year earlier. Full-year consensus is $-7.64, growing to $-7.86 the year after.
REVENUE · NEXT QUARTER
$3.8K
Range $0 – $13.0K · 7 analysts · -74% YoY
Revenue is expected to reach $3.8K (range $0 – $13.0K), -74.5% year-over-year. Full-year consensus is $11.7K, rising to $6.7M next year.
Top analysts covering Lyell Immunopharma Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on LYEL.
#1
Mitchell Kapoor
HC Wainwright & Co. · Rank #165
Buy
$45.00+246.2% to target
Overall win rate
34%
+ Follow
#2
Reni J. Benjamin
JMP Securities · Rank #290
Buy
$34.00+161.5% to target
Overall win rate
33%
+ Follow
#3
Gil Blum
Needham · Rank #298
Buy
$44.00+238.5% to target
Overall win rate
24%
+ Follow
#4
Reni J. Benjamin
Citizens
Buy
$34.00+161.5% to target
Coverage
—
+ Follow
#5
JA
Jack Allen
Baird
Buy
$49.00+276.9% to target
Coverage
—
+ Follow
LYEL stock forecast FAQ
What is LYEL's average 12-month price target?+
The 4 analysts with a live target average $35.75 for Lyell Immunopharma Inc over the next 12 months, ranging from a $45.00 high to a $20.00 low.
Is LYEL stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 4 analyst ratings, 4 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for LYEL?+
The Street-high target is $45.00 (HC Wainwright & Co.), and the Street-low is $20.00 (LUCID CAPITAL MARKETS). The average of all 4 active targets is $35.75.
How many Wall Street analysts cover LYEL?+
4 analysts have an active rating on Lyell Immunopharma Inc, and 4 firms carry a live 12-month price target.
Who is the most accurate analyst covering LYEL?+
Among analysts who currently cover LYEL, Mitchell Kapoor of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #165). Their current call is Buy with a $45.00 target.
What is Lyell Immunopharma Inc's projected EPS for next quarter?+
The consensus estimate is $-2.09 per share (range $-2.35 – $-1.90) across 7 analysts. Full-year EPS is projected at $-7.64, rising to $-7.86 the following year.
How much revenue is Lyell Immunopharma Inc expected to report next quarter?+
Consensus revenue is $3.8K (range $0 – $13.0K). Full-year revenue is projected at $11.7K, growing to $6.7M next year.
Have analysts been upgrading or downgrading LYEL lately?+
As of Jul, 4 of 4 firms rate LYEL a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their LYEL calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
